B.S., University of Michigan, 1977
M.D., Duke University School of Medicine, 1980
Research Statement
Dr. David Harlan is interested in identifying the immunological mechanisms that underlie the pathogenesis of type 1 diabetes mellitus (T1DM) and/or the rejection organs/tissues transplanted to treat that disease. To those ends, his group utilizes molecular, cellular, and small animal models to elucidate immunological mechanisms. In addition, he is actively involved in clinical protocols to test whether immune modifying reagents can ameliorate disease severity in individuals with recently diagnosed T1DM, and to transplant pancreatic islets into individuals with long standing and "brittle" T1DM. For the latter, he and his colleagues have developed a non-human primate model to test novel approaches to improve islet transplant technology.
Back to Top
Selected Publications
1. Pechhold K Patterson NB Blum C Fleischacker CL Boehm BO Harlan DM Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent. J Immunol (166): 2531-9, 2001. [Full Text/Abstract]
2. Blair PJ Riley JL Harlan DM Abe R Tadaki DK Hoffmann SC White L Francomano T Perfetto SJ Kirk AD June CH CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med (191): 651-60, 2000. [Full Text/Abstract]
3. Kenyon NS Chatzipetrou M Masetti M Ranuncoli A Oliveira M Wagner JL Kirk AD Harlan DM Burkly LC Ricordi C Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A (96): 8132-7, 1999. [Full Text/Abstract]
4. Harlan DM Kirk AD The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA (282): 1076-82, 1999. [Full Text/Abstract]
5. Kirk AD Burkly LC Batty DS Baumgartner RE Berning JD Buchanan K Fechner JH Jr Germond RL Kampen RL Patterson NB Swanson SJ Tadaki DK TenHoor CN White L Knechtle SJ Harlan DM Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med (5): 686-93, 1999. [Full Text/Abstract]
